Damien M Cronier Selected Research

olaratumab

1/2020	Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
1/2019	Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
1/2018	Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
1/2017	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
7/2016	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Damien M Cronier Research Topics

Disease

6	Neoplasms (Cancer) 01/2018 - 06/2014
5	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 07/2016
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 01/2016
2	Disease Progression 01/2019 - 01/2017
2	Glioblastoma (Glioblastoma Multiforme) 01/2018 - 01/2016
2	Multiple Myeloma 03/2017 - 12/2016
2	Vomiting 07/2016 - 01/2015
2	Nausea 07/2016 - 01/2015
2	Melanoma (Melanoma, Malignant) 03/2016 - 01/2016
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2015 - 03/2012
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2018
1	Body Weight (Weight, Body) 01/2018
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017
1	Febrile Neutropenia 07/2016
1	Neutropenia 07/2016
1	Mucositis 07/2016
1	Colorectal Neoplasms (Colorectal Cancer) 01/2016
1	Breast Neoplasms (Breast Cancer) 01/2016
1	Aspiration Pneumonia 01/2015
1	Leukemia 06/2014
1	Fatigue 03/2012
1	Chills 03/2012

Drug/Important Bio-Agent (IBA)

5	olaratumabIBA 01/2020 - 07/2016
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 07/2016
4	abemaciclibIBA 01/2018 - 07/2014
3	Monoclonal AntibodiesIBA 01/2018 - 01/2015
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2018 - 01/2016
2	Bortezomib (Velcade)FDA Link 03/2017 - 12/2016
2	tabalumabIBA 03/2017 - 12/2016
2	B-Cell Activating FactorIBA 03/2017 - 12/2016
2	Biomarkers (Surrogate Marker)IBA 03/2016 - 07/2014
2	ocaratuzumabIBA 01/2015 - 03/2012
1	Dexamethasone (Maxidex)FDA LinkGeneric 03/2017
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2017
1	Growth Factor ReceptorsIBA 07/2016
1	AnthracyclinesIBA 07/2016
1	VemurafenibIBA 03/2016
1	Hormones (Hormone)IBA 01/2016
1	Pharmaceutical PreparationsIBA 01/2015
1	Cyclin-Dependent Kinase 4IBA 07/2014
1	Cytostatic AgentsIBA 07/2014
1	Phosphotransferases (Kinase)IBA 06/2014
1	N1- (4- (3- isopropyl- 2- methylindazol- 5- yl)pyrimidin- 2- yl)- N4- tetrahydropyran- 4- yl- cyclohexane- 1,4- diamineIBA 06/2014
1	Proteins (Proteins, Gene)FDA Link 06/2014

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2018 - 07/2016
1	Intravenous Administration 01/2020